David Sallman, MD, Moffit Cancer Center, Tampa, FL, talks on the use of radioisotopes in the treatment of acute myeloid leukemia (AML), commenting on the Phase III SIERRA study (NCT02074839) evaluating Iomab-B, a radio-immunotherapy, prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in older patients with relapsed/refractory (R/R) AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.